This session cuts through longevity hype and emphasized why it is important to focus on scientifically validated, clinically relevant, and practically actionable care only. It explores how to distinguish robust evidence from speculation, marketing, and experimental care, and debates why more common sense is required in the longevity conversation: Enjoying life, friendship, and balance to achieve a high- quality lifestyle.  

This session critically examines emerging longevity interventions, including NMN, exosomes, vagus nerve stimulation, photobiomodulation, and more. It assesses biological rationale, clinical evidence, regulatory status, real-world outcomes, highlighting where promise is justified, where risks remain, and how clinicians, investors, and patients should interpret rapidly evolving claims.

Cardiovascular disease remains the dominant driver of early mortality worldwide. This session focuses on evidence-based prevention strategies, from advanced risk stratification and lipid management to lifestyle, digital monitoring, and system-level interventions. It highlights where prevention delivers the greatest longevity impact and how to translate guidelines into measurable, long-term outcomes.

Women live longer than men, yet experience different disease trajectories and unique health risks across the lifespan. This session explores sex-specific biology, cardiovascular and metabolic differences, hormonal transitions, and data gaps, highlighting how tailored prevention, research, and care models can significantly improve healthspan and outcomes for women.

This session critically evaluates the most popular dietary supplements in longevity and preventive medicine. It reviews mechanistic claims, clinical evidence, and placebo effects, distinguishing meaningful interventions from marketing-driven products. Participants gain a practical framework to assess supplement efficacy, safety, and relevance within evidence-based longevity and prevention strategies.

Most people will face complex medical decisions at some point in their lives. This session uses real patient stories to illustrate how important it is to know how to navigate the healthcare system when becoming a patient. It offers practical lessons on preparation, advocacy, second opinions, and decision-making to help patients reduce avoidable harm and navigate care more effectively.

This session explores how employers can move beyond symbolic wellness perks to deliver measurable health and productivity outcomes. It examines preventive programs, personalized health services, data-driven incentives, and alignment with corporate strategy, showing how well-designed health benefits reduce risk, improve engagement, and create long-term value for employees and organizations.

Preventive medicine has the potential to improve population health while reducing long-term costs. This session examines how insurers and public healthcare systems can scale prevention through data, incentives, and care redesign. It discusses access, equity, economic trade-offs, and implementation barriers shaping the future of prevention at system level.

Longevity has emerged as a rapidly expanding investment theme, attracting capital across biotech, diagnostics, digital health, and services. This session reviews market size assumptions, deal flow, valuation dynamics, and recent transactions, separating durable opportunities from hype and highlighting where capital can generate both financial returns and real health impact.

Regenerative medicine promises transformative therapies. This session examines where stem cell applications are evidence-based today, where they remain experimental, and how regulation, manufacturing, and safety shape adoption. It offers a realistic outlook on near-term clinical use versus longer-term regenerative potential. 

While cancer is one of the biggest risks of our lifetime, novel early diagnostics promise to substantially reduce risk by ultra-early detection before tumors even start to form. This session explores evidence-based strategies to reduce cancer risk through lifestyle, early detection, genetics, environmental exposure management, and emerging preventive interventions—highlighting what is realistically achievable today and where future breakthroughs may further shift outcomes. 

Living longer comes with substantial costs—particularly for internationally mobile families. This session examines the true costs of longevity, serious illness, and end-of-life care across jurisdictions. It provides practical frameworks for anticipating healthcare expenses, aligning insurance and assets, and preparing families for complex decisions long before they arise.

This session addresses assisted dying from ethical, medical, legal, and societal perspectives. It examines differing international frameworks, physician responsibilities, patient autonomy, and safeguards against misuse. The discussion highlights real-world implications for patients, families, clinicians, and healthcare systems navigating end-of-life decisions with dignity and accountability.

Cognitive decline is one of the greatest fears of aging, yet many risk factors are modifiable. This session explores evidence-based strategies for cognitive longevity, including cardiovascular health, sleep, nutrition, mental stimulation, and emerging diagnostics, offering practical insights on how to preserve brain function and resilience well into later life.